PURPOSE: The androgen receptor (AR) is intensively discussed as a prognostic and/or predictive marker in breast cancer patients. METHODS: We evaluated the value of AR mRNA expression with the Affymetrix HG-U 133A array in 3 different cohorts: a cohort of breast cancer patients who received adjuvant treatment (cohort A; n = 165), a cohort of untreated breast cancer patients (cohort B; n = 200) and a cohort of chemotherapy-treated breast cancer patients with estrogen receptor (ER)-positive tumors (cohort C; n = 223). RESULTS: AR mRNA expression was associated with lower grading (Grades 1 and 2) as well as ER and progesterone receptor (PgR) positivity in all cohorts. In the treated cohort (cohort A), low androgen receptor expression was associated with shorter event-free survival (OR 2,34, 95 % CI 1.01-5.43, p = 0.047) which was not seen in the untreated cohort B. Subgroup analysis revealed that shorter survival of patients with low AR mRNA expression was observed mainly in the ER-positive subgroup of patients treated with adjuvant chemotherapy. In the validation cohort C we could confirm a benefit of chemotherapy for the group of tumors with high AR mRNA expression (5-year event-free survival (EFS) 74 % versus 57 %, p = 0.013). In this cohort, low AR mRNA expression was associated with shorter event-free survival also in multivariate analysis (OR 2.86, 95 % CI 1.29-6.35, p = 0.010) adjusted for HER2, ki-67, tumor size, age and tumor grade. CONCLUSIONS: We provide evidence that AR expression is associated with chemotherapy responsiveness in ER-positive patients.
PURPOSE: The androgen receptor (AR) is intensively discussed as a prognostic and/or predictive marker in breast cancerpatients. METHODS: We evaluated the value of AR mRNA expression with the Affymetrix HG-U 133A array in 3 different cohorts: a cohort of breast cancerpatients who received adjuvant treatment (cohort A; n = 165), a cohort of untreated breast cancerpatients (cohort B; n = 200) and a cohort of chemotherapy-treated breast cancerpatients with estrogen receptor (ER)-positive tumors (cohort C; n = 223). RESULTS:AR mRNA expression was associated with lower grading (Grades 1 and 2) as well as ER and progesterone receptor (PgR) positivity in all cohorts. In the treated cohort (cohort A), low androgen receptor expression was associated with shorter event-free survival (OR 2,34, 95 % CI 1.01-5.43, p = 0.047) which was not seen in the untreated cohort B. Subgroup analysis revealed that shorter survival of patients with low AR mRNA expression was observed mainly in the ER-positive subgroup of patients treated with adjuvant chemotherapy. In the validation cohort C we could confirm a benefit of chemotherapy for the group of tumors with high AR mRNA expression (5-year event-free survival (EFS) 74 % versus 57 %, p = 0.013). In this cohort, low AR mRNA expression was associated with shorter event-free survival also in multivariate analysis (OR 2.86, 95 % CI 1.29-6.35, p = 0.010) adjusted for HER2, ki-67, tumor size, age and tumor grade. CONCLUSIONS: We provide evidence that AR expression is associated with chemotherapy responsiveness in ER-positive patients.
Authors: Seho Park; Hyung Seok Park; Ja Seung Koo; Woo Ick Yang; Seung Il Kim; Byeong-Woo Park Journal: Breast Cancer Res Treat Date: 2012-01-10 Impact factor: 4.872
Authors: Isabella Castellano; Elena Allia; Valeria Accortanzo; Anna Maria Vandone; Luigi Chiusa; Riccardo Arisio; Antonio Durando; Michela Donadio; Gianni Bussolati; Alan S Coates; Giuseppe Viale; Anna Sapino Journal: Breast Cancer Res Treat Date: 2010-02-03 Impact factor: 4.872
Authors: Amelia A Peters; Grant Buchanan; Carmela Ricciardelli; Tina Bianco-Miotto; Margaret M Centenera; Jonathan M Harris; Shalini Jindal; Davendra Segara; Li Jia; Nicole L Moore; Susan M Henshall; Stephen N Birrell; Gerhard A Coetzee; Robert L Sutherland; Lisa M Butler; Wayne D Tilley Journal: Cancer Res Date: 2009-07-28 Impact factor: 12.701
Authors: Luis O Gonzalez; Maria D Corte; Julio Vazquez; Sara Junquera; Rosario Sanchez; Ana C Alvarez; Juan C Rodriguez; Maria L Lamelas; Francisco J Vizoso Journal: BMC Cancer Date: 2008-05-28 Impact factor: 4.430
Authors: Tracy Proverbs-Singh; Jarett L Feldman; Michael J Morris; Karen A Autio; Tiffany A Traina Journal: Endocr Relat Cancer Date: 2015-02-26 Impact factor: 5.678
Authors: J Feng; L Li; N Zhang; J Liu; L Zhang; H Gao; G Wang; Y Li; Y Zhang; X Li; D Liu; J Lu; B Huang Journal: Oncogene Date: 2016-11-28 Impact factor: 9.867
Authors: Suriyan Ponnusamy; Sarah Asemota; Lee S Schwartzberg; Fouzia Guestini; Keely M McNamara; Mariaelena Pierobon; Alba Font-Tello; Xintao Qiu; Yingtian Xie; Prakash K Rao; Thirumagal Thiyagarajan; Brandy Grimes; Daniel L Johnson; Martin D Fleming; Frances E Pritchard; Michael P Berry; Roy Oswaks; Richard E Fine; Myles Brown; Hironobu Sasano; Emanuel F Petricoin; Henry W Long; Ramesh Narayanan Journal: iScience Date: 2019-10-23
Authors: Milena Rondón-Lagos; Victoria E Villegas; Nelson Rangel; Magda Carolina Sánchez; Peter G Zaphiropoulos Journal: Int J Mol Sci Date: 2016-08-19 Impact factor: 5.923
Authors: Nadine Tung; Judy E Garber; Michele R Hacker; Vanda Torous; Gordon J Freeman; Emily Poles; Scott Rodig; Brian Alexander; Larissa Lee; Laura C Collins; Stuart J Schnitt Journal: NPJ Breast Cancer Date: 2016-02-24